[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100378045":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":7,"locations":7,"responsibleParty":19,"collaborators":7,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":26,"eligibilityCriteria":27,"healthyVolunteers":23,"sex":28,"minAge":29,"maxAge":7,"enrollmentInfo":30,"targetDuration":7,"studyType":33,"phases":7,"briefSummary":34,"conditions":35,"keywords":37,"overallStatus":41,"whyStopped":7,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"LEO Pharma","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Ingenol mebutate","Topical field treatment as prescribed by dermatologist",[14],"Picato",[16],{"name":17,"affiliation":5,"role":18},"Sarah Moumane, MD","STUDY_CHAIR",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100378045","treatment-of-actinic-keratosis-lesions--pharmacoepidemiological-study-of-the-impact-in-real-life-of-ingenol-mebutate-gel-picato-on-patients-satisfaction-100378045",false,"NCT04202445","TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction","MIKADO","Inclusion Criteria:\n\n* Patient at least 18 years old, seen by the dermatologist during a consultation, whether actinic keratosis is the reason for consultation or not.\n* Patient with AK lesions and for whom the dermatologist decided to initiate a treatment with Picato®\\* 150 or Picato®\\* 500\n* Patient informed and accepting the automatic processing of medical data \\* To respect the physicians' independence, this study is conducted among patients for whom the decision of therapeutic care is not related to their inclusion.\n\nExclusion Criteria:\n\n* Patient with a contraindication to treatment with Picato®.\n* Patient unable to read and\u002For to understand a self-administered questionnaire.\n* Patient already included in the study.\n* Patient participating or having participated in the previous month in a clinical trial in dermatology.","ALL","18 Years",{"count":31,"type":32},1218,"ACTUAL","OBSERVATIONAL","This is an observational longitudinal study, prospective, multicenter, performed in metropolitan France, on a representative sample of dermatologists.\n\nData will be collected by physicians during 2 or 3 visits (according to their usual practice), from the patient file, questioning and clinical examination performed during these visits.\n\nData about the patient's perception (satisfaction, perception of local skin reactions, quality of life) will be collected directly by the patient using self-administered questionnaires at inclusion visit, day 7 and 2 months later.",[36],"Actinic Keratosis",[38,39,11,14,40],"Actinic keratosis","Field treatment","Mikado","COMPLETED","2023-06-08",{"date":44,"type":32},"2023-06-09",{"date":46,"type":32},"2014-04",{"date":48,"type":32},"2016-02",{"name":5,"class":6}]